Exiqon A/S (NASDAQ OMX: EXQ), a leading provider of technologies for biomarker
detection, today announced the introduction of GLP compliant services for miRNA
biomarker screening and diagnostic assay development for clinical trials.

Exiqon is already working with a number of global pharmaceutical companies in
the search for biomarkers to support their clinical programs on future drugs,
programs to support current drugs or to rescue failed drugs.

The experiences gathered from these collaborations have now been comprised in a
new product offering for services provided under the guidelines of OECD's
principles of Good Laboratory Practice (GLP) in support of ongoing clinical
trials.

Exiqon can provide a full suite of services to support miRNA biomarker
diagnostic programs in both clinical FFPE tissue as well as bio fluids. Exiqon
provides complete project design, samples isolation and processing and
biomarker analysis using Exiqon's LNA technology. Exiqon also provides
bioinformatics packages to support technical development and interpretation of
biomarker data.

Exiqons unique position as a leader in the field of miRNAs means that customers
get access to Exiqon's very extensive Data-biobank of miRNA data. For clinical
tissue samples Exiqon has a tumor database containing hundreds of miRNA
profiles from all major cancer types which can be used to support projects.

Exiqon has one of the world's largest collections of blood serum and plasma
miRNA data containing thousands or samples from diseased and normal
individuals. This is an unparalleled resource in allowing rapid development and
high quality QC of customer projects based on a leading understanding of miRNAs
in blood.

”This clinical partnering service capability is a natural complement to our
internal diagnostic programs and harness all the processes and infrastructure
we have developed to drive our own diagnostics pipeline”, says Adam Baker,
Director, Diagnostics and Pharma Services.

This recent addition to Exiqon's product offering allows the company to further
exploit its position as the world's leading miRNA company to deliver customized
high quality contract research services for clinical research and companion
diagnostic programs to its partners based on Exiqon's proprietary LNA™
detection technology and miRNA biomarkers.

See the full press release in the attached PDF.



Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090
2101)
Adam Baker, Director Diagnostics and Pharma Services, tel. +45 4565
0986 (cell: +45 4090 2153)

GLP Compliant Services.pdf